Medicinal preparation for urinary calculi and preparation method thereof
By combining pharmaceutical preparations of natural plants such as the inverted Shield Vine, the problem of poor treatment effect of urinary stones in the existing technology has been solved, significantly improved the stone-soluble effect and ability to prevent recurrence, and effective treatment of urinary stones has been achieved. and prevention.
Patent Information
- Application Number
- CN202411245986.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the treatment of urinary stones, the stone removal effect is not strong enough, the stone dissolution effect is not outstanding, and the prevention and prevention of recurrence is weak.
A pharmaceutical preparation consisting of inverted Shield-winged Vine, cone Snake Vine, kidney tea, coix root, cereal, moth, ash leaf tree and licorice, was soaked in water, decocted, concentrated under reduced pressure and The steps of drying and other steps are made into granules, which use the synergistic effects of these natural plants to enhance the effects of fossils, diuresis, detoxification and dissolving calcium oxalate.
It significantly promotes the dissolution of calcium oxalate, improves the therapeutic effect on urinary stones, reduces the risk of recurrence of stones, and enhances the litholysis and prevention ability of the drug by increasing the content of rosemary acid and total flavonoids.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to a technology in the field of ethnic medicine, specifically a Dai medicine preparation for urinary calculi and a preparation method thereof. Background Art
[0002] Urinary stones include kidney stones, urinary tract stones and bladder stones. Surgical treatment is one of the effective methods for treating urinary stones, but it is expensive, has a poor prognosis, and the efficiency of lithotripsy is low. According to the development of current medical conditions, more and more patients are found in the early stage, and drug therapy has gradually become the first choice for stones with a diameter of less than 6mm. Summary of the invention
[0003] The present invention aims to solve the shortcomings of the prior art that the stone-removing effect is not strong enough, the stone-dissolving effect is not prominent, and the prevention and recurrence prevention effects are weak. A pharmaceutical preparation for urinary stones and a preparation method thereof are proposed. The various medicinal ingredients in the prescription act synergistically and have the advantages of no toxic side effects.
[0004] The present invention is achieved through the following technical solutions:
[0005] The invention relates to a method for preparing a pharmaceutical preparation for urinary calculi. The method comprises the following steps: selecting raw material pieces for decoction, soaking them in water, decocting them twice, and reducing the pressure on the filtrate to concentrate it, wherein the raw materials and their mass percentages are 20%-40% of Herba Lycopodii, 5%-15% of Celastrus conus, 15%-25% of Herba Glehniae, 5%-15% of Coix lachryma-jobi, 5%-15% of Semen Plantaginis, 5%-15% of Herba Lysimachiae, 5%-15% of Herba Glehniae, and 2%-5% of Radix Glycyrrhizae.
[0006] The Aspidopterys obcordata Hemsl. is the dried vine stem of Aspidopterys obcordata Hemsl.
[0007] The described Celastrus paniculatus Willd. is the dried vine stem of Celastrus paniculatus Willd.
[0008] The kidney tea is the dried aerial part of Clerodendranthus spicatus (Thunb.) CYWu.
[0009] The coix root is the dried root of Coixlacryma-jobi L.var.ma-yuen (Roman.)Stapf harvested in autumn.
[0010] The psyllium seeds are dry mature seeds harvested in summer and / or autumn from Plantago asiatica L. or Plantago depressa Willd.
[0011] The money grass is the dried whole grass of Lysimachia christinae Hance harvested in summer or autumn.
[0012] The ash-leaved tree is the dry, peeled stem wood of Viburnum cylindricum Buch.-Ham.ex D.Don felled in autumn or winter.
[0013] The licorice is the dry roots and rhizomes of Glycyrrhiza uralensis Fisch. or Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L. harvested in spring or autumn and with fibrous roots removed.
[0014] The preparation is preferably prepared by concentrating the thick paste into fine powder, and then adding the ingredients to form granules.
[0015] The ingredients include but are not limited to sweeteners.
[0016] The filtrate is combined with the filtrate obtained by two decoctions and filtrations.
[0017] The raw materials and their mass percentages are preferably: 30% of Celastrus invertebrata, 10% of Celastrus cone, 20% of Herba Coix, 10% of Coix lachryma-jobi, 8% of Plantago, 9% of Lysimachia chinensis, 10% of Psoralea corylifolia and 3% of Licorice.
[0018] The preparation method is specifically as follows: select raw material slices and add 10 times the amount of water to soak for 0.5h, heat and extract repeatedly twice, each time for 1h, combine the filtrate and concentrate to a thick paste of 1.30 (g / mL) (50°C) under -0.08Mpa. The obtained thick paste is dried under -0.06Mpa and 80°C and crushed to fine powder. Add an appropriate amount of 80% ethanol dissolved with 5g of aspartame as a wetting agent, prepare a soft material, prepare granules, dry at 80°C, granulate, and pack 10g / bag to obtain granules. Technical Effects
[0019] All the medicinal materials in the present invention are natural plant ethnic medicinal materials. The prescription is based on the Dai medicine theory. The Herba Corydalis in the prescription is bitter, cool in nature, and enters the water tower, which is the main medicine; the root of Coix lachryma-jobi is sweet and light, cool in nature, and enters the water tower and the earth tower, which are also the main medicines. The herba griseae is slightly astringent, flat in nature, and enters the water tower and the earth tower; the herba spatholobi is slightly astringent, cool in nature, and enters the wind tower, the water tower, and the earth tower; the herba spatholobi is bitter, cool in nature, and enters the water tower and the earth tower; the herba plantaine is sweet, slightly cold in nature, and enters the water tower; the herba spatholobi is sweet, salty, and slightly cold in nature. These five medicines jointly help the main medicine to enhance the effects of fossilization, diuresis, and detoxification, and are auxiliary medicines. Licorice can not only help the main medicine and auxiliary medicine to enhance the therapeutic effect, but also can be used to prepare the cold and cool diuretic medicine in the prescription, and reconcile the various medicines, and is a reconciling medicine. The whole formula can be used together to play the role of clearing heat and detoxifying, promoting diuresis and dissolving stones, cooling blood and stopping bleeding. The content of the main active ingredient rosmarinic acid reaches 7.53%, and the content of total flavonoids in the main effective parts reaches 0.28%.
[0020] The method achieves and enhances the effective treatment and / or relief of urinary stones (kidney stones, bladder stones) through the modified formula (added Plantago, Lysimachia chinensis and Glechoma longituba), can significantly or extremely significantly promote the dissolution of calcium oxalate (P<0.05 or P<0.01), increases the lithotripsy effect, and can prevent or control the occurrence or recurrence of urinary stones. DETAILED DESCRIPTION Example 1
[0021] The raw materials used in this embodiment and their weight percentages are: 40% of Herba Lycopodii, 5% of Celastrus conophytum, 15% of Herba Coicis, 5% of Coix lachryma-jobi, 5% of Semen Plantaginis, 15% of Herba Lysimachiae, 13% of Herba Lycopodii, and 2% of Radix Glycyrrhizae.
[0022] The preparation process of this embodiment is as follows:
[0023] Step 1) Take the prescribed amount of decoction pieces and add 6 times the amount of water to soak for 0.3h;
[0024] Step 2) After soaking the slices, boil for 0.5h and filter to obtain the filtrate. Add 6 times the amount of water to the residue and boil for 0.5h, then filter. Combine the two filtrates, concentrate under reduced pressure (-0.08Mpa) to a thick paste of 1.30 (g / mL) (50°C), and set aside;
[0025] Step 3) drying the thick paste at 70° C. under a vacuum condition of -0.06 MPa, crushing it, and passing it through a 100-mesh sieve to obtain fine drug powder for later use;
[0026] Step 4) Add an appropriate amount of 70% ethanol dissolved with 3 g of aspartame to the fine powder of the drug as a wetting agent, prepare a soft material, prepare granules, dry at 60° C., and pack in 10 g / bag to obtain granules.
[0027] The method is used to prepare brown-yellow granules, wherein the scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, plantago asiatica, lycopodiella cuneata and liquorice can be identified by thin layer chromatography, the content of rosmarinic acid is 5.05%, and the content of total flavonoids is 0.21%. Example 2
[0028] The raw materials used in this embodiment and their weight percentages are: 20% of Celastrus invertebrata, 10% of Celastrus cone, 20% of Herba Coix, 7% of Coix lachryma-jobi, 15% of Plantago, 15% of Lysimachia chinensis, 10% of Psoralea corylifolia, and 3% of Licorice.
[0029] The preparation process of this embodiment is as follows:
[0030] Step 1) Take the prescribed amount of decoction pieces and add 12 times the amount of water to soak for 0.3h;
[0031] Step 2) After soaking the slices, boil them for 1 hour and filter to obtain the filtrate. Add 12 times the amount of water to the residue and boil them for 1 hour, then filter. Combine the two filtrates, concentrate under reduced pressure (-0.08Mpa) to a thick paste of 1.30 (g / mL) (50°C), and set aside;
[0032] Step 3) drying the thick paste at 80° C. under a vacuum condition of -0.06 MPa, crushing, sieving, and obtaining fine drug powder for later use;
[0033] Step 4) Add an appropriate amount of 80% ethanol dissolved with 5 g of aspartame to the fine powder of the drug as a wetting agent, prepare a soft material, prepare granules, dry at 80° C., and pack in 10 g / bag to obtain granules.
[0034] The method is used to prepare brown-yellow granules, wherein the scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, plantago asiatica, scutellaria baicalensis and licorice can be identified by thin layer chromatography, the content of rosmarinic acid is 6.75%, and the content of total flavonoids is 0.18%. Example 3
[0035] The raw materials used in this embodiment and their weight percentages are: 30% of Celastrus invertebrata, 15% of Celastrus cone, 15% of Herba Coix, 15% of Coix lachryma-jobi, 5% of Plantago, 5% of Lysimachia chinensis, 10% of Psoralea corylifolia, and 5% of Licorice.
[0036] The preparation process of this embodiment is as follows:
[0037] Step 1) Take the prescribed amount of decoction pieces and add 8 times the amount of water to soak for 0.5h;
[0038] Step 2) After soaking the slices, boil them for 1.5 hours and filter to obtain the filtrate. Add 8 times the amount of water to the residue and boil them for another 1.5 hours and filter. Combine the two filtrates, concentrate under reduced pressure (-0.08Mpa) to a thick paste of 1.30 (g / mL) (50°C) and set aside;
[0039] Step 3) drying the thick paste at 70° C. under a vacuum condition of -0.06 MPa, crushing it, and passing it through a 100-mesh sieve to obtain fine drug powder for later use;
[0040] Step 4) Add an appropriate amount of 90% ethanol dissolved with 7 g of aspartame to the fine powder of the drug as a wetting agent, prepare a soft material, prepare granules, dry at 70° C., and pack in 10 g / bag to obtain granules.
[0041] The method is used to prepare brown-yellow granules, wherein the scutellaria baicalensis, scutellaria baicalensis cone, scutellaria sphaerocephala, plantago asiatica, scutellaria baicalensis and licorice can be identified by thin layer chromatography, the content of rosmarinic acid is 5.56%, and the content of total flavonoids is 0.15%. Example 4
[0042] The raw materials used in this embodiment and their weight percentages are: 30% of Herba Lycopodii, 10% of Celastrus paniculatus, 20% of Herba Cynoglossi, 10% of Coix lachryma-jobi, 8% of Semen Plantaginis, 9% of Herba Lysimachiae, 10% of Herba Lycopodii, and 3% of Radix Glycyrrhizae.
[0043] The preparation process of this embodiment is as follows:
[0044] Step 1) Take the prescribed amount of decoction pieces and add 10 times the amount of water to soak for 0.5h;
[0045] Step 2) After soaking the slices, boil them for 1 hour and filter to obtain the filtrate. Add 10 times the amount of water to the residue and boil them for 1 hour, then filter. Combine the two filtrates, concentrate under reduced pressure (-0.08Mpa) to a thick paste of 1.30 (g / mL) (50°C), and set aside;
[0046] Step 3) drying the thick paste at 80° C. under a vacuum condition of -0.06 MPa, crushing, sieving, and obtaining fine drug powder for later use;
[0047] Step 4) Add an appropriate amount of 80% ethanol dissolved with 5 g of aspartame into the fine powder of the drug as a wetting agent, prepare a soft material, prepare granules, dry at 80° C., and pack in 10 g / bags to obtain granules.
[0048] The method is used to prepare brown-yellow granules, wherein the scutellaria baicalensis, scutellaria baicalensis cone, scutellaria sphaerocephala, plantago asiatica, scutellaria baicalensis and licorice can be identified by thin layer chromatography, the content of rosmarinic acid is 7.53%, and the content of total flavonoids is 0.28%. Example 5
[0049] The drug of the present invention was evaluated for its pharmacodynamic effect by using a rat ethylenediamine stone model and the effect on the in vitro dissolution of calcium oxalate. Specifically, SD male rats weighing 180-200g were taken and fed normally for one week, and then randomly divided into a modeling group and a normal group. The normal group had normal drinking water, and the modeling group rats had drinking water (containing 2% ethylene glycol and 1% ammonium chloride) for four consecutive weeks. After the modeling, the modeling group animals were randomly divided into a model group, a flavored group (prepared according to the best embodiment 4), a original group (prepared with granules in the manner described in Chinese patent document number CN101829188A), and a stone-removing granule group. The model group was gavaged with pure water, the flavored group was given Shishiqinglin granules, the positive group was given stone-removing granules, and the original group was given original granules. The administration volume was 0.5mL / , and there were 10 animals in each group. The drug was administered for 2 consecutive weeks. One day before the end of the experiment, the rats were placed in a metabolic cage and 24-hour urine was collected. After rats were anesthetized with sodium pentobarbital, blood was collected from the abdominal artery. After rats were killed, both kidneys were removed and frozen tissue sections were made. The sections were observed for the presence of crystalline particles under a light microscope, and image analysis or crystal number counting and histopathological observation were performed. The total amount of inosine and urea in serum and creatinine clearance were determined, and the total amount of inosine and urinary calcium in urine were determined.
[0050] Step 1) Effects on rat urine biochemical parameters
[0051] Table 1 Urine creatinine (Cr), Ca 2+ Effect of content (n=10)
[0052] Note: * P<0.05, ** P<0.01vs normal control group; # P<0.05, ## P<0.01vs model group.
[0053] As shown in the table, the Ca 2+ The addition group, original prescription group and positive group significantly reduced creatinine (Cr) and Ca 2+ It has a significant effect on excretion, and the added flavor group has a stronger effect than the original group.
[0054] Step 2) Effects on serum biochemical parameters of rats
[0055] Table 2 Effects on creatinine (Cr), urea (BUN) and creatinine clearance (Ccr) in rat serum (n=10)
[0056] Note: * P<0.05, ** P<0.01vs normal control group; #P<0.05, ## P<0.01vs model group
[0057] As can be seen from the table, there were significant differences in blood creatinine (Cr), urea (BUN) and creatinine clearance rate (Ccr) between the model group and the normal group (P<0.05); compared with the model group, the added group, the original group and the positive group could reduce blood creatinine (Cr) and increase creatinine clearance rate (Ccr), and could significantly reduce urea content (P<0.05), and the added group had a stronger effect than the original group.
[0058] Step 3) Effect on the area occupied by stones in rat kidney tissue
[0059] Table 3 Effect on the area occupied by stones in renal tissue (n=10)
[0060] ** P<0.01vs normal control group; ## P<0.01vs model group
[0061] As can be seen from the table, no stones were found in the renal tissue of rats in the normal group, and the model group was significantly different from the normal group, indicating that the model was successful; compared with the model group, the added group, the original group and the positive group could significantly reduce the area occupied by stones in the renal tissue (P<0.01), and the area occupied by stones in the added group was smaller than that in the original group, and the effect of treating kidney stones was stronger.
[0062] In summary, 2% ethylenediamine and 1% ammonium chloride mixed in water and fed for four consecutive weeks can cause kidney stones in SD rats. The corresponding drugs were given at regular intervals every day for 2 weeks. After the administration, the urine and blood biochemical indicators of the rats were tested. The flavored group had a better effect in protecting kidney function, reducing blood urea content, increasing creatinine clearance, and reducing the area occupied by kidney stones. Example 6
[0063] Effects on bladder stones caused by foreign bodies
[0064] SD male rats weighing 180-200g were taken. After one week of normal feeding, 10 rats were randomly selected as the sham operation group. The rats were anesthetized with ether, and the skin and muscles were cut longitudinally in the middle of the abdomen, and the abdomen was closed accordingly. The remaining animals were the model group. After the rats were anesthetized, the skin and muscles were cut longitudinally in the middle of the abdomen, a small cut was made at the top of the bladder, and a 2cm surgical sterile silk thread was implanted into the rat bladder. The wound was sutured with a purse string. After 4 weeks, the rats with successful modeling were randomly divided into groups, with 10 animals in each group. The model group was gavaged with pure water, the flavored group was given Shishi Qinglin granules, the positive group was given Paishi granules, and the original group was given patented granules. They were killed after 2 weeks to observe the effect on the stone weight.
[0065] Step 1) Effects on rat body weight, kidney, kidney-to-body weight ratio, and stone weight
[0066] Table 5 Effects on rat body weight, kidney, kidney-to-body weight ratio and stone weight (n=10)
[0067] Note: * P<0.05, ** P<0.01vs normal control group; # P<0.05, ## P<0.01vs model group
[0068] After modeling, the body weight of rats in the model group, the modified group, the original group, and the positive group decreased significantly or extremely significantly (P<0.05). There was no significant difference in the kidney weight ratio among the groups, indicating that the model did not cause kidney enlargement. The stone weight showed that compared with the model group, the modified group and the positive group could inhibit bladder stones (P<0.05), and the modified group had a stronger inhibitory effect than the original group.
[0069] Step 2) Effects on serum biochemical parameters of rats
[0070] Table 6 Effects on creatinine (Cr), urea (Bun) and creatinine clearance (Ccr) in rat serum (n=10)
[0071] Note: * P<0.05, ** P<0.01vs normal control group; # P<0.05, ## P<0.01vs model group
[0072] As can be seen from the table, there was no significant difference in creatinine (Cr), urea (Bun) and creatinine clearance (Ccr) among the rats in each group, indicating that the renal function of each group was normal and bladder stones did not affect the renal function.
[0073] In summary, foreign bodies buried in the bladder can cause bladder stones. Rats were divided into groups and given drugs 4 weeks after foreign bodies were buried in the bladder. Bladder stones did not significantly affect kidney function and cause renal edema, but surgical modeling still caused significant weight loss in rats. Compared with the model group, the flavored group can treat bladder stones. Example 7
[0074] Effects on the dissolution of calcium oxalate in vitro
[0075] Using distilled water and saline as controls, the dissolution of calcium oxalate by different concentrations of Shishiqinglin granules, Paishi granules, and original group granules was observed. Shishiqinglin granules, Paishi granules, and original group granules were diluted with distilled water to (1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200), 10 mL of each was taken, and incubated with 0.1 g of calcium oxalate in a conical flask. Each group was incubated 4 times, and after ultrasonication for 10 minutes, the supernatant was shaken at 37°C and 250 rpm for 3 hours, and centrifuged at 10000 rpm / min to determine the calcium ion content.
[0076] Table 4 Effect of different concentrations of drug diluents on the dissolution of calcium oxalate (n=4)
[0077] Note: * indicates P<0.05; ** indicates P<0.01.
[0078] The granules in the modified group, the positive group and the original group all promoted the dissolution of calcium oxalate in a dose-dependent manner. At dilutions of 1:100, 1:200 and 1:400, both of them could significantly or extremely significantly promote the dissolution of calcium oxalate (P<0.05 or P<0.01).
[0079] Compared with the prior art, the content of rosmarinic acid and total flavonoids in the preparation obtained by this method is increased to 7.53% and 0.28% respectively. It significantly reduces the creatinine (Cr) and Ca in the urine of the ethylenediamine-induced stone model. 2+ content and serum creatinine (Cr) and urea (BUN) content, and improve creatinine clearance (Ccr). The preparation and stone-removing granules obtained by this method can significantly dissolve calcium oxalate in vitro, and significantly inhibit the formation of stones caused by foreign bodies in the bladder. The original group of granules has no dissolving effect at the current concentration. This method achieves and enhances the effective treatment and / or relief of urinary stones (kidney stones, bladder stones) through the addition of a formula (added Plantago, Lysimachia chinensis and Glechoma longituba), can significantly or extremely significantly promote the dissolution of calcium oxalate (P<0.05 or P<0.01), increase the stone-dissolving effect, and can prevent or control the occurrence or recurrence of urinary stones.
[0080] The above-mentioned specific implementation can be partially adjusted in different ways by those skilled in the art without departing from the principle and purpose of the present invention. The protection scope of the present invention shall be based on the claims and shall not be limited by the above-mentioned specific implementation. Each implementation scheme within its scope shall be subject to the constraints of the present invention.
Claims
1. A method for preparing a pharmaceutical preparation for urinary calculi, characterized in that: The raw material pieces are selected, soaked in water and then decocted twice, and the filtrate is reduced pressure and concentrated to make the product, wherein the raw materials and their mass percentages are 20%-40% of Herba Corydalis, 5%-15% of Celastrus conus, 15%-25% of Herba Spatholobi, 5%-15% of Coix lachryma-jobi root, 5%-15% of Plantago seed, 5%-15% of Herba Lysimachiae, 5%-15% of Herba Glehniae, and 2%-5% of Licorice.
2. The method for preparing the pharmaceutical preparation for urinary calculi according to claim 1, characterized in that: The inverted shield-winged vine is the dried vine stem of Aspidopterys obcordata Hemsl.; the cone-shaped southern snake vine is the dried vine stem of Celastrus paniculatus Willd.; the kidney tea is the dried aerial part of Clerodendranthus spicatus (Thunb.) CYWu; the coix root is the dried root of Coix lacryma-jobi L.var.ma-yuen (Roman.) Stapf harvested in autumn; the plantain seeds are the dried mature seeds of Plantago asiatica L. or Plantago depressa Willd. harvested in summer and / or autumn; the money grass is the dried whole grass of Lysimachia christinae Hance harvested in summer or autumn; the gray-leaved tree is the dried peeled stem wood of Viburnumcylindricum Buch.-Ham.ex D.Don harvested in autumn or winter; the licorice is Glycyrrhiza uralensis Fisch. or Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L. The dried roots and rhizomes with the fibrous roots removed are harvested in spring or autumn.
3. The method for preparing the pharmaceutical preparation for urinary calculi according to claim 1, characterized in that: The preparation is prepared by concentrating the thick paste into fine powder, and then adding ingredients to form granules.
4. The method for preparing the pharmaceutical preparation for urinary calculi according to claim 1, characterized in that: The ingredients include sweeteners.
5. The method for preparing the pharmaceutical preparation for urinary calculi according to claim 1, characterized in that: The filtrate is combined with the filtrate obtained by two decoctions and filtrations.
6. The method for preparing the pharmaceutical preparation for urinary calculi according to claim 1, characterized in that: The raw materials and their mass percentages are: 30% of scutellaria baicalensis, 10% of orbiculatus cone, 20% of scutellaria baicalensis, 10% of coix root, 8% of plantain seed, 9% of moneywort, 10% of ash leaf tree and 3% of liquorice.
7. The method for preparing the pharmaceutical preparation for urinary calculi according to claim 1, characterized in that: Select raw material slices and soak them in 10 times the amount of water for 0.5h. Repeat the extraction by heating twice, each time for 1h. After combining the filtrate, concentrate it to a thick paste of 1.30 (g / mL) (50°C) under -0.08Mpa. The obtained thick paste is dried at -0.06Mpa, 80°C, crushed to fine powder, added with an appropriate amount of 80% ethanol dissolved with 5g of aspartame as a wetting agent, prepared into a soft material, prepared into granules, dried at 80°C, granulated, and packaged in 10g / bags to obtain granules.
Citation Information
Patent Citations
Medicament for treating urinary infection and lithiasis
CN101829188A
Medicament for treating urinary calculus and benign prostatic hyperplasia
CN101856388A
